INDIANAPOLIS — Drugmaker Eli Lilly and Co. is restricting access to a drug discount program intended for safety-net hospitals in a move the company says is needed to identify waste, fraud and abuse.
The Indianapolis-based pharmaceutical company now requires hospitals to submit insurance claims data for in-house pharmacy dispensing to qualify for discount pricing through the federal 340B program — an expansion of the company’s long-standing reporting requirements.
“That data is necessary to identify unlawful duplicate discounts, audit covered entities, initiate HRSA’s dispute-resolution process, and comply with obligations under the Inflation Reduction Act,” Josh O’Harra, senior vice president and deputy general counsel for Eli Lilly, said in a June letter to the federal Health Resources and Services Administration…